CARTITUDE-4 Study1,2

CARTITUDE-4 is a randomized, open label, multicenter controlled study in adult patients with relapsed and lenalidomide-refractory multiple myeloma, who previously received at least 1 prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. A total of 419 patients were randomized 1:1 to receive either a sequence of apheresis, bridging therapy, lymphodepletion, and CARVYKTI® (n=208) or standard therapy which included daratumumab, pomalidomide, and dexamethasone (DPd) or bortezomib, pomalidomide, and dexamethasone (PVd) selected by physician prior to randomization based on patient’s prior antimyeloma therapy (n=211).

Expand Icon
CARVYKTI® (ciltacabtagene autoleucel) CARTITUDE-4 study design

Primary Endpoint:
PFS (Intent-to-Treat)

Select Secondary Endpoints||:
CR or better, ORR (sCR + CR + VGPR + PR), OS

CAR+=chimeric antigen receptor-positive; CR=complete response; DOR=duration of response; IMWG=International Myeloma Working Group; IRC=Independent Review Committee; IV=intravenous infusion; LoT=line(s) of therapy; ORR=overall response rate; OS=overall survival; PFS=progression-free survival; PR=partial response; sCR=stringent complete response; VGPR=very good partial response.

*Randomization was stratified by physician’s choice of treatment (DPd vs PVd), ISS (I vs II vs III) and number of prior lines of therapy (1 vs 2 or 3).

Per the IMWG consensus, assessed by IRC.

80.8% of patients received 1-2 cycles of standard therapy. Maximum received was 6 cycles in 1 patient.

§The remaining 32 patients discontinued trial participation before receiving CARVYKTI®, predominantly because of disease
progression during bridging therapy or lymphodepletion. Of these patients, 20 received CARVYKTI® as a subsequent therapy.1

||Secondary outcomes were sequentially tested at each prespecified significance level, including (in order) rates of CR or better, ORR.2

ELIGIBILITY CRITERIA1,2

Key Inclusion Criteria

  • Adult patients with RRMM
  • Received 1-3 prior LoT including a PI
    and an immunomodulatory agent
  • Refractory to lenalidomide
  • ECOG PS 0-1

Key Exclusion Criteria

  • Prior CAR-T or BCMA-targeting therapy
  • Known active or prior history of central nervous system involvement
  • Exhibit clinical signs of meningeal involvement of multiple myeloma
  • History of Parkinson’s disease or other neurodegenerative disorder

BCMA=B-cell maturation antigen; CAR-T=chimeric antigen receptor-T cell; ECOG PS=Eastern Cooperative Oncology Group performance status; LoT=line(s) of therapy; PI=proteasome inhibitor; RRMM=relapsed or refractory multiple myeloma.

CARTITUDE-4 STUDY:
BASELINE CHARACTERISTICS (N=419)1,2

You are now viewing an analysis from the CARTITUDE-4 trial. This information is not included in the current USPI.

CHARACTERISTICCARVYKTI® (n=208)STANDARD THERAPY (n=211)
Median age, years (range)61.5 (27-78)61.0 (35-80)
Male, n (%)116 (55.8)124 (58.8)
Race or ethnic group, n (%)*
Asian16 (7.7)20 (9.5)
Black6 (2.9)7 (3.3)
White157 (75.5)157 (74.4)
Other1 (0.5)1 (0.5)
Missing data28 (13.5)26 (12.3)
Hispanic or Latino ethnic group, n (%)*
Hispanic or Latino18 (8.7)10 (4.7)
Not Hispanic or Latino152 (73.1)165 (78.2)
Missing data38 (18.3)36 (17.1)
Geographic region
Europe128 (61.5)129 (61.1)
North America32 (15.4)32 (15.2)
Asia27 (13.0)25 (11.8)
Australia21 (10.1)25 (11.8)
ECOG PS score, n (%)
0114 (54.8)121 (57.3)
193 (44.7)89 (42.2)
21 (0.5)1 (0.5)
ISS stage, n (%)
I136 (65.4)132 (62.6)
II60 (28.8)65 (30.8)
III12 (5.8)14 (6.6)
Median time since diagnosis, years (range)3.0 (0.3-18.1)3.4 (0.4-22.1)
Presence of soft-tissue plasmacytomas, n (%)44 (21.2)35 (16.6)
Bone marrow plasma cells >60%§, n/total n (%)42/206 (20.4)43/208 (20.7)
Cytogenetic risk, n/total n (%)
Standard risk69/207 (33.3)70/210 (33.3)
High cytogenetic risk, n/N (%)||123/207 (59.4)132/210 (62.9)
Gain/amp(1q)89/207 (43.0)107/210 (51.0)
del(17p)49/207 (23.7)43/210 (20.5)
t(4;14)30/207 (14.5)30/210 (14.3)
t(14;16)3/207 (1.4)7/210 (3.3)
With ≥2 high-risk mutations43/207 (20.8)49/210 (23.2)
With del(17p), t(4;14), or t(14;16)73/207 (35.3)69/210 (32.9)
Missing data15/207 (7.2)8/210 (3.8)
Tumor BCMA expression ≥50%, n (%)141 (67.8)138 (65.4)
Prior lines of therapy, n (%)
168 (32.7)68 (32.2)
283 (39.9)87 (41.2)
357 (27.4)56 (26.5)
Prior immunomodulatory agents, n (%)208 (100.0)211 (100.0)
Lenalidomide208 (100.0)211 (100.0)
Pomalidomide8 (3.8)10 (4.7)
Prior anti-CD38 antibody, n (%)53 (25.5)55 (26.1)
Daratumumab51 (24.5)54 (25.6)
Isatuximab2 (1.0)2 (0.9)
Prior proteasome inhibitor, n (%)208 (100.0)211 (100.0)
Bortezomib203 (97.6)205 (97.2)
Carfilzomib77 (37.0)66 (31.3)
Ixazomib21 (10.1)21 (10.0)
Triple-class exposed, n (%)53 (25.5)55 (26.1)
Penta-drug# exposed, n (%)14 (6.7)10 (4.7)
Refractory status, n (%)
Lenalidomide208 (100.0)211 (100.0)
Bortezomib55 (26.4)48 (22.7)
Carfilzomib51 (24.5)45 (21.3)
Any anti-CD38 antibody50 (24.0)46 (21.8)
Daratumumab48 (23.1)45 (21.3)
Ixazomib15 (7.2)17 (8.1)
Pomalidomide8 (3.8)9 (4.3)
Triple-class30 (14.4)33 (15.6)
Penta-drug#2 (1.0)1 (0.5)

amp=amplification; BCMA=B-cell maturation antigen; CD38=cluster of differentiation 38; del=deletion; ECOG PS=Eastern Cooperative Oncology Group performance status; Gain/amp=gain or amplification; ISS=International Staging System; t=translocation; USPI=US Prescribing Information.

*Race or ethnic group was reported by the patients. Among the patients who were enrolled in the United States, 9 (14.1%) were Black. The designation of “Other” includes American Indian and Alaska Native ethnic groups.

Listed is the latest available performance-status score on the Eastern Cooperative Oncology Group (ECOG) scale that was recorded on or before the initiation of apheresis or cycle 1. All the patients met the inclusion criteria of an ECOG performance-status score of 0 or 1 before randomization.

Soft-tissue plasmacytomas include extramedullary and bone-based plasmacytomas with a measurable soft-tissue component.

§In the measurement of bone marrow plasma cells, the maximum value from bone marrow biopsy and bone marrow aspirate was selected if both results were available.

High-risk cytogenetics, presence of t(4:14), (14:16), and 17p13 del, were present in 34% of patients.

Triple-class therapy includes one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody.

#Penta-drug therapy includes at least 2 proteasome inhibitors, at least two immunomodulatory agents, and one anti-CD38 monoclonal antibody.

Powerful Results

In CARTITUDE-4 at 15.9 Months

Expand Icon

CARVYKTI® SIGNIFICANTLY PROLONGED Progression-Free Survival (PRIMARY ENDPOINT) vs STANDARD THERAPY (DPd or PVd)1*

PROGRESSION-FREE SURVIVAL

Graph of progression-free survival (PFS) primary analysis for CARVYKTI® intent-to-treat population

PFS SUBGROUP ANALYSIS

PFS SUBGROUP ANALYSIS

Percentages rounded to nearest whole number.

CI=confidence interval; DPd=daratumumab, pomalidomide, and dexamethasone; HR=hazard ratio; mPFS=median progression-free survival; PVd=pomalidomide, bortezomib, and dexamethasone.

*Median follow-up was 15.9 months in the Intent-to-Treat Analysis Set.

PROGRESSION-FREE SURVIVAL

In CARTITUDE-4 at 15.9 Months*

Expand Icon

The following data is based on a post hoc analysis of patients that received cilta-cel as study treatment. Patients who progressed or died prior to cilta-cel infusion were excluded from this analysis. Therefore, these data should be interpreted with caution and considered as supportive evidence regarding cilta-cel efficacy. This information is not contained in the USPI.

PROGRESSION-FREE SURVIVAL4

Graph of progression-free survival (PFS) primary analysis for CARVYKTI® as-treated population

Percentage rounded to nearest whole number.

mPFS=median progression-free survival; USPI=US Prescribing Information.

*Median follow-up was 15.9 months in the As-Treated Analysis Set.

Overall Survival

In CARTITUDE-4 at 15.9 Months*

Expand Icon

MEDIAN OVERALL SURVIVAL (OS) WAS NOT REACHED
AT 12 MONTHS WITH CARVYKTI®1

OVERALL SURVIVAL1,5*

Graph of overall survival (OS) for CARVYKTI® versus standard therapy
  • 34% of the planned OS events have occurred
  • Within the first 10 months of randomization, a higher proportion of patients in the CARVYKTI®. arm died compared to the standard
    therapy arm. Click here for Infusion and Monitoring ConsiderationsOS Redirect Icon

Percentages rounded to nearest whole number.

CI=confidence interval; mOS=median overall survival.

*Median follow-up was 15.9 months in the Intent-to-Treat Analysis Set.

Deep Responses3*

In CARTITUDE-4 at 15.9 Months

Expand Icon

85% OVERALL RESPONSE RATE WAS ACHIEVED WITH CARVYKTI®, AND 81% OF PATIENTS ACHIEVED A DEEP RESPONSE1,2*

OVERALL RESPONSE RATE

Deep response is defined as ≥VGPR

Bar chart of CARTITUDE-4 depth of response for CARVYKTI® intent-to-treat population

Percentages rounded to nearest whole number and may not add up due to rounding.

CI=confidence interval; CR=complete response; DPd=daratumumab, pomalidomide, and dexamethasone; ORR=overall response rate; PR=partial response; PVd=pomalidomide, bortezomib, and dexamethasone; sCR=stringent complete response; VGPR=very good partial response.

*Median follow-up was 15.9 months in the Intent-to-Treat Analysis Set.

Includes patients who achieved PR or better.

Overall Response Rate

In CARTITUDE-4 at 15.9 Months*

Expand Icon

The following data is based on a post hoc analysis of patients that received cilta-cel as study treatment. Patients who progressed or died prior to cilta-cel infusion were excluded from this analysis. Therefore, these data should be interpreted with caution and considered as supportive evidence regarding cilta-cel efficacy. This information is not contained in the USPI.

OVERALL RESPONSE RATE4*

Bar chart of CARTITUDE-4 depth of response for CARVYKTI® as-treated population

Percentages rounded to nearest whole number and may not add up due to rounding.

CR=complete response; ORR=overall response rate; PR=partial response; sCR=stringent complete response; USPI=US Prescribing Information; VGPR=very good partial response.

*Median follow-up was 15.9 months in the As-Treated Analysis Set.

Includes patients who achieved PR or better.

Durable responses

In CARTITUDE-4 at 15.9 months

Expand Icon

Median Duration of Response for CARVYKTI® Was Not Reached1*

MEDIAN DURATION OF RESPONSE

CARVYKTI® (N=208) not reached versus standard therapy (N=211) 16.6 months

CI=confidence interval; CR=complete response; DPd=daratumumab, pomalidomide, and dexamethasone; mDOR=median duration of response; NE=not estimable; PR=partial response; PVd=pomalidomide, bortezomib, and dexamethasone.

*Median follow-up was 15.9 months in the Intent-to-Treat Analysis Set.

Estimated mDOR.

Learn More About CARVYKTI®